Skip to main content

Asparlas Side Effects

Generic name: calaspargase pegol

Medically reviewed by Last updated on Nov 19, 2023.

Note: This document contains side effect information about calaspargase pegol. Some dosage forms listed on this page may not apply to the brand name Asparlas.

Applies to calaspargase pegol: intravenous solution.

Serious side effects of Asparlas

Along with its needed effects, calaspargase pegol (the active ingredient contained in Asparlas) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking calaspargase pegol:

More common

Less common

Other side effects of Asparlas

Some side effects of calaspargase pegol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to calaspargase pegol: intravenous solution.


Very common (10% or more): Abnormal clotting (e.g., activated partial thromboplastin time prolonged, blood fibrinogen decreased; diarrhea: colitis, diarrhea, enterocolitis, neutropenic colitis) (14%)

Common (1% to 10%): Embolic/thrombotic events (e.g., device related thrombosis, disseminated intravascular coagulation, embolism, intracardiac thrombus, intracranial venous sinus thrombosis, pulmonary embolism, superior sagittal sinus thrombosis, thrombosis in device, venous thrombosis, venous thrombosis limb), hemorrhage (e.g., disseminated intravascular coagulation, epistaxis, hematoma, hemorrhage intracranial, melena, esophageal ulcer hemorrhage, small intestinal hemorrhage, upper GI hemorrhage)[Ref]


Common (1% to 10%): Hypersensitivity[Ref]


Common (1% to 10%): Sepsis (e.g., bacterial sepsis, sepsis), fungal infection (e.g., fungal infection, hepatic infection fungal, respiratory tract infection fungal, splenic infection fungal, systemic candida)

Frequency not reported: Immunogenicity[Ref]


Very common (10% or more): Elevated transaminase (e.g., alanine aminotransferase increased, aspartate aminotransferase increased, transaminases increased) (52%), bilirubin increased (e.g., bilirubin conjugated increased, blood bilirubin increased) (20%)[Ref]


Common (1% to 10%): Dyspnea (e.g., hypoxia, respiratory failure), pneumonia (e.g., lung infection, pneumonia, pneumonitis)[Ref]


Common (1% to 10%): Arrhythmia (e.g., atrioventricular block complete, sinus tachycardia, ventricular arrhythmia), cardiac failure (e.g., ejection fraction decreased, left ventricular dysfunction)[Ref]


Very common (10% or more): Pancreatitis (e.g., amylase increased, lipase increased, pancreatic necrosis, pancreatitis, pancreatitis relapsing) (18%)

Common (1% to 10%): Diarrhea[Ref]

Frequently asked questions


1. Product Information. Asparlas (calaspargase pegol). Servier. 2019.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.